Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been granted de novo classification by the U.S. Food and Drug Administration (FDA) for the Early Bird® Bleed Monitoring System.
Scheduled presentations of interest include a moderated poster session by Philippe Généreux, MD, Saranas Chief Medical Officer and Co-Director of the Structural Heart Disease Program at Morristown Medical Center, Morristown, New Jersey, on Thursday, June 21 at 11:30 AM. Dr. Généreux will present results from the FDA-mandated validation study designed to assess the performance and safety of the Early Bird® Bleed Monitoring System.
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced the completion of a $2.8 million Series C funding round.
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an application requesting Agency review and de novo classification of the Early Bird® Bleed Monitoring System.
Saranas, a medical device company with a cutting-edge technology for real-time detection and monitoring of internal bleeding during endovascular procedures, placed first runner-up at the Cardiovascular Research Technologies (CRT) competition on March 6, 2018, in Washington, D.C.Read More
Saranas, a medical device company with a new technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced the company was named as one of the Top 4 Innovators at the International Conference for Innovations in Cardiovascular Systems (ICI) in Tel Aviv, Israel.Read More
Saranas, a medical device company with a new technology for real-time detection and monitoring of internal bleeding during endovascular procedures, has been invited to present at the 29th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation (CRF), Oct. 31, 2017, in Denver, CO. Saranas was chosen to participate in the conference’s Shark Tank Competition.Read More
Zaffer Syed is the president and CEO of Saranas, a medical technology company operating at TMCx, the Texas Medical Center's startup incubator.Read More
Recognized for its ability to avoid pain, scarring, and long recovery times, minimally invasive vascular access procedures (VAP) continues to gain popularity year over year. That said, VAP does have inherent risks, with patients in nearly 20 percent of cases seeing at least some negative impact related to bleeding. Saranas is a Texas-based company that is focused on minimizing these risks by providing early detection and monitoring of internal bleeding complications via bioimpedance measurements.Read More
Saranas, a medical device company with a new technology for real-time detection of internal bleeding during cardiac procedures, today announced the appointment of Dr. Philippe Généreux as its Chief Medical Officer.Read More
Saranas, a medical device company with a new technology for real-time detection of internal bleeding during cardiac procedures, has closed a $4 million Series B round of financing. The funding will be used to advance the company’s Early Bird® Bleed Detection device through final product testing and FDA submission later this year.Read More
angelMD announced the closure of a new syndicate investment in Saranas, a promising new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this first investment in Saranas by angelMD members, and this angelMD syndicate is part of Saranas’ recently announced $4 million Series B financing round.Read More
Now, I will show how you can balance clinical and entrepreneurial efforts. First, let’s dispense with the 800-pound gorilla lurking in the corner: Unless you are overwhelmed with a constant flurry of real game-changing ideas — and let me assure you are not regardless of any contrary conviction— the worst thing you can do is to abandon or significantly curtail your clinical practice.If you became a physician for any reason other than improving your parents’ conditions you should stop reading now because this article isn’t written for you. The term “balance” makes clear enough that this is for those entrepreneurs who are determined to continue their clinical practice.Read More
In this retrospective cohort study of 17 672 consecutive patients who underwent a transcatheter aortic valve replacement, endovascular aneurysm repair, or percutaneous left ventricular assist device implant, 18% experienced bleeding complications. Patients with bleeding complications (compared with those without) had increased in-hospital mortality, length of stay, and health care cost.Read More
Money is not the most important thing in life. Time is. And if you think this is a platitude, you should spend a day in the shoes of the practicing physician who is trying to make the world better. Not only by his or her patient contacts, but by conceiving, nurturing and ultimately bringing to market technologies that — with intelligence, grit and a bit of luck — will impact larger numbers of patients than one will ever meet in an entire career.Read More
Houstonians have been lauding the city’s economic diversity for months as the Bayou City has continued to feel the effects of low oil prices. Specifically, business leaders and economists have pointed to the health care and biotech industries as the lifeboat for the city’s downturn.Read More
Saranas, a Houston medical device company, expects to announce this week that it has raised $2.35 million to further develop a souped-up sheath that can detect blood leaks caused by catheters in real time. The funding came from existing investors, including members of the GOOSE Society, such as Vanguard Ventures co-founder Jack Gill, and Houston Angel Network members.Read More
While catheter-based interventional procedures have major advantages, there’s always a chance that a vessel can get ruptured when introducing the sheath through which instruments are snaked to the treatment site. Undetected, this kind of bleeding can have serious consequences for patients, sometimes even leading to death. A new device from Saranas, a Houston, Texas firm, may soon be commonplace in cath labs for detecting bleeding due to ruptured vessels.Read More
Product innovator Cambridge Consultants has been chosen by Texas biomedical start-up Saranas to help develop an early-warning system for bleeding complications during interventional catheter-based procedures. The device is aimed at medical procedures requiring access to a blood vessel – such as transcatheter aortic valve replacements (TAVRs), where the femoral artery is used to gain access to the heart.Read More
This year about 20 million patients in the U.S. will undergo a procedure in which a doctor will thread a catheter into a blood vessel to treat a cardiac ailment, say, or provide dialysis or chemotherapy. But in five percent of these “vascular-access procedures,” the catheter accidentally punctures the vessel, causing a slow leak of blood that can be hard to detect—but which can wind up wreaking havoc. Houston medtech startup Saranas says it’s developed a device that can detect the bleeding within a matter of minutes.Read More
The Houston Technology Center (HTC) has just revealed the winners of its 2013 Goradia Innovation Prize. This event of recognition, in collaboration with Opportunity Houston, awards nearly $150,000 in cash during the 2013 Innovation Conference and Showcase to individual finalists and starting companies that have yet to largely commercialize their innovations in the Texas Gulf Coast region. The winners are selected based on their discovery’s commercial potential, a sound business plan, potential to contribute to local job growth, and likelihood of success in the long run.Read More
The Ken Kennedy Institute for Information Technology (K2I) is dedicated to the advancement of research in the fields of computing, data science and information technology. Our goal is to provide broad support for a strong community of research experimentation that challenges traditional disciplinary limits.Read More